Long-term safety of admilparant in people with pulmonary fibrosis
Checks long-term safety of admilparant in people who finished earlier pulmonary fibrosis studies.
Plain-language title generated from the registry record
Registry title: Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Key facts
- Where
- Angers, Bobigny, Brest, Bron, Dijon, Grenoble Cedex 9, Marseille, Nice, Paris Cedex 18, Pessac, Saint-Herblain, and Toulouse, FranceSee the 12 sites
- Phase
- Phase 3
Where in France
- Centre Hospitalier Universitaire D'AngersAngers, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisBobigny, FranceNot yet recruiting
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranceNot yet recruiting
- Hospices Civils de LyonBron, FranceNot yet recruiting
- Centre Hospitalier Universitaire de DijonDijon, FranceNot yet recruiting
- Centre Hospitalier Universitaire Grenoble AlpesGrenoble Cedex 9, FranceNot yet recruiting
- Centre Hospitalier Regional De MarseilleMarseille, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NiceNice, FranceNot yet recruiting
- Assistance Publique Hopitaux De ParisParis Cedex 18, FranceNot yet recruiting
- Centre Hospitalier Universitaire de BordeauxPessac, FranceNot yet recruiting
- Centre Hospitalier Universitaire de NantesSaint-Herblain, FranceNot yet recruiting
- Centre Hospitalier Universitaire de ToulouseToulouse, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT07441408EU 2025-522373-10-00
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).Read full original descriptionShow less
An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
Inclusion: Participants must have participated in either IM027068 or IM0271015 without discontinuing treatment permanently due to withdrawal of informed consent in either IM027068 or IM0271015.
Exclusion: Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation; Exhibit symptoms of heart failure at rest; History of lung reduction surgery or lung transplant; Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single-drug therapy that now requires multi-drug therapy; Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015; Other protocol-defined Inclusion/Exclusion criteria apply.